Ocaliva

Chemical Nameobeticholic acid
Dosage FormTablet (oral; 5 mg, 10 mg)
Drug ClassReceptor agonists
SystemDigestive
CompanyIntercept Pharms Inc
Approval Year2016

Indication

  • For the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.
Last updated on 12/21/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Ocaliva (obeticholic acid) Prescribing Information 2019Intercept Pharmaceuticals, Inc., New York, NY